• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用可解释机器学习降低单克隆抗体黏度。

Reduction of monoclonal antibody viscosity using interpretable machine learning.

机构信息

Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.

Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.

出版信息

MAbs. 2024 Jan-Dec;16(1):2303781. doi: 10.1080/19420862.2024.2303781. Epub 2024 Mar 12.

DOI:10.1080/19420862.2024.2303781
PMID:38475982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10939158/
Abstract

Early identification of antibody candidates with drug-like properties is essential for simplifying the development of safe and effective antibody therapeutics. For subcutaneous administration, it is important to identify candidates with low self-association to enable their formulation at high concentration while maintaining low viscosity, opalescence, and aggregation. Here, we report an interpretable machine learning model for predicting antibody (IgG1) variants with low viscosity using only the sequences of their variable (Fv) regions. Our model was trained on antibody viscosity data (>100 mg/mL mAb concentration) obtained at a common formulation pH (pH 5.2), and it identifies three key Fv features of antibodies linked to viscosity, namely their isoelectric points, hydrophobic patch sizes, and numbers of negatively charged patches. Of the three features, most predicted antibodies at risk for high viscosity, including antibodies with diverse antibody germlines in our study (79 mAbs) as well as clinical-stage IgG1s (94 mAbs), are those with low Fv isoelectric points (Fv pIs < 6.3). Our model identifies viscous antibodies with relatively high accuracy not only in our training and test sets, but also for previously reported data. Importantly, we show that the interpretable nature of the model enables the design of mutations that significantly reduce antibody viscosity, which we confirmed experimentally. We expect that this approach can be readily integrated into the drug development process to reduce the need for experimental viscosity screening and improve the identification of antibody candidates with drug-like properties.

摘要

早期识别具有类药性的抗体候选物对于简化安全有效的抗体治疗药物的开发至关重要。对于皮下给药,识别具有低自缔合特性的候选物很重要,这可以使其在高浓度下形成制剂,同时保持低粘度、低光学不透明度和低聚集性。在这里,我们报告了一种可解释的机器学习模型,用于仅使用其可变(Fv)区的序列预测具有低粘度的抗体(IgG1)变体。我们的模型是在常见制剂 pH(pH 5.2)下获得的抗体粘度数据(>100mg/mL mAb 浓度)上进行训练的,它确定了与粘度相关的三个关键 Fv 特征,即它们的等电点、疏水性补丁大小和带负电荷的补丁数量。在这三个特征中,大多数预测的高粘度风险抗体,包括我们研究中具有多样化抗体胚系的抗体(79 种 mAbs)以及临床阶段的 IgG1(94 种 mAbs),都是那些 Fv 等电点较低(Fv pI < 6.3)的抗体。我们的模型不仅在我们的训练集和测试集中,而且在以前报道的数据中,都能以相对较高的准确度识别粘性抗体。重要的是,我们表明模型的可解释性质能够设计出显著降低抗体粘度的突变,我们通过实验证实了这一点。我们预计这种方法可以很容易地整合到药物开发过程中,以减少对实验性粘度筛选的需求,并提高具有类药性的抗体候选物的识别能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/4e8b535af2c7/KMAB_A_2303781_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/266d80bf1520/KMAB_A_2303781_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/01fdbc6f473d/KMAB_A_2303781_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/df5f12ccd1ec/KMAB_A_2303781_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/0b8e40cabdd8/KMAB_A_2303781_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/b89b2c8c27a4/KMAB_A_2303781_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/c93106f8de17/KMAB_A_2303781_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/11aaaca99a82/KMAB_A_2303781_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/4e8b535af2c7/KMAB_A_2303781_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/266d80bf1520/KMAB_A_2303781_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/01fdbc6f473d/KMAB_A_2303781_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/df5f12ccd1ec/KMAB_A_2303781_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/0b8e40cabdd8/KMAB_A_2303781_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/b89b2c8c27a4/KMAB_A_2303781_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/c93106f8de17/KMAB_A_2303781_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/11aaaca99a82/KMAB_A_2303781_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7168/10939158/4e8b535af2c7/KMAB_A_2303781_F0008_OC.jpg

相似文献

1
Reduction of monoclonal antibody viscosity using interpretable machine learning.使用可解释机器学习降低单克隆抗体黏度。
MAbs. 2024 Jan-Dec;16(1):2303781. doi: 10.1080/19420862.2024.2303781. Epub 2024 Mar 12.
2
Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.等电点较弱的抗体可最大限度减少配方和生理胶体性质之间的权衡。
Mol Pharm. 2022 Mar 7;19(3):775-787. doi: 10.1021/acs.molpharmaceut.1c00373. Epub 2022 Feb 2.
3
Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.单克隆抗体减粘突变体的合理设计:疏水与静电分子间相互作用
MAbs. 2015;7(1):212-30. doi: 10.4161/19420862.2014.985504.
4
Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering.通过合理的、基于结构引导的Fv工程减轻人IgG1单克隆抗体中的可逆自缔合和粘度
MAbs. 2016 Jul;8(5):941-50. doi: 10.1080/19420862.2016.1171444. Epub 2016 Apr 6.
5
Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations.高粘性抗体溶液是由结构域-结构域静电互补性导致的网络形成的结果:来自粗粒度模拟的见解。
Mol Pharm. 2015 Jan 5;12(1):127-39. doi: 10.1021/mp500485w. Epub 2014 Nov 20.
6
Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties.单克隆抗体溶液的浓度依赖性粘度:从分子特性角度解释实验行为
Pharm Res. 2014 Nov;31(11):3161-78. doi: 10.1007/s11095-014-1409-0. Epub 2014 Jun 7.
7
Structure-based charge calculations for predicting isoelectric point, viscosity, clearance, and profiling antibody therapeutics.基于结构的电荷计算预测等电点、黏度、清除率和分析抗体治疗药物。
MAbs. 2021 Jan-Dec;13(1):1981805. doi: 10.1080/19420862.2021.1981805.
8
Molecular computations of preferential interactions of proline, arginine.HCl, and NaCl with IgG1 antibodies and their impact on aggregation and viscosity.脯氨酸、精氨酸盐酸盐和 NaCl 与 IgG1 抗体优先相互作用的分子计算及其对聚集和粘度的影响。
MAbs. 2020 Jan-Dec;12(1):1816312. doi: 10.1080/19420862.2020.1816312.
9
Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.人源 IgG1 和 IgG4 S228P 单克隆抗体的黏度和自身相互作用的差异:结构域相互作用的实验评估和计算预测。
MAbs. 2021 Jan-Dec;13(1):1991256. doi: 10.1080/19420862.2021.1991256.
10
Assessing the Impact of Charge Variants on Stability and Viscosity of a High Concentration Antibody Formulation.评估电荷变异对高浓度抗体制剂稳定性和黏度的影响。
J Pharm Sci. 2017 Dec;106(12):3507-3514. doi: 10.1016/j.xphs.2017.08.016. Epub 2017 Aug 30.

引用本文的文献

1
Optimizing colloidal stability and viscosity of multispecific antibodies at the drug discovery-development interface: a systematic predictive case study.在药物发现与开发界面优化多特异性抗体的胶体稳定性和粘度:一项系统预测性案例研究
MAbs. 2025 Dec;17(1):2553622. doi: 10.1080/19420862.2025.2553622. Epub 2025 Sep 1.
2
Harnessing computational technologies to facilitate antibody-drug conjugate development.利用计算技术促进抗体药物偶联物的开发。
Nat Chem Biol. 2025 Jun 27. doi: 10.1038/s41589-025-01950-z.
3
Explainable Artificial Intelligence in the Field of Drug Research.

本文引用的文献

1
Development of in silico models to predict viscosity and mouse clearance using a comprehensive analytical data set collected on 83 scaffold-consistent monoclonal antibodies.利用综合分析数据集开发预测黏度和小鼠清除率的计算模型,该数据集涵盖了 83 种支架一致的单克隆抗体。
MAbs. 2023 Jan-Dec;15(1):2256745. doi: 10.1080/19420862.2023.2256745.
2
Optimization of therapeutic antibodies for reduced self-association and non-specific binding via interpretable machine learning.通过可解释的机器学习优化治疗性抗体以减少自身聚集和非特异性结合。
Nat Biomed Eng. 2024 Jan;8(1):45-56. doi: 10.1038/s41551-023-01074-6. Epub 2023 Sep 4.
3
药物研究领域中的可解释人工智能
Drug Des Devel Ther. 2025 May 29;19:4501-4516. doi: 10.2147/DDDT.S525171. eCollection 2025.
4
Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning.利用大规模粘度数据和集成深度学习加速高浓度单克隆抗体开发
MAbs. 2025 Dec;17(1):2483944. doi: 10.1080/19420862.2025.2483944. Epub 2025 Apr 1.
5
PROPERMAB: an integrative framework for prediction of antibody developability using machine learning.PROPERMAB:一种使用机器学习预测抗体可开发性的综合框架。
MAbs. 2025 Dec;17(1):2474521. doi: 10.1080/19420862.2025.2474521. Epub 2025 Mar 5.
6
Reconciling predicted and measured viscosity parameters in high concentration therapeutic antibody solutions.调和高浓度治疗性抗体溶液中预测粘度参数与实测粘度参数
MAbs. 2024 Jan-Dec;16(1):2438172. doi: 10.1080/19420862.2024.2438172. Epub 2024 Dec 11.
7
Hybrid Mass Spectrometry Applied across the Production of Antibody Biotherapeutics.混合质谱在抗体生物治疗药物生产中的应用
J Am Soc Mass Spectrom. 2025 Jan 1;36(1):44-57. doi: 10.1021/jasms.4c00253. Epub 2024 Nov 21.
8
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability.天然和人工改造抗体景观的生物物理作图定量评估了抗体可开发性的可塑性。
Commun Biol. 2024 Jul 31;7(1):922. doi: 10.1038/s42003-024-06561-3.
9
A framework for the biophysical screening of antibody mutations targeting solvent-accessible hydrophobic and electrostatic patches for enhanced viscosity profiles.一个用于对靶向溶剂可及疏水和亲水区域的抗体突变进行生物物理筛选以增强粘度特征的框架。
Comput Struct Biotechnol J. 2024 May 24;23:2345-2357. doi: 10.1016/j.csbj.2024.05.041. eCollection 2024 Dec.
Assessing developability early in the discovery process for novel biologics.
评估新型生物制剂发现过程中的可开发性。
MAbs. 2023 Jan-Dec;15(1):2171248. doi: 10.1080/19420862.2023.2171248.
4
Low-data interpretable deep learning prediction of antibody viscosity using a biophysically meaningful representation.使用具有物理意义的表示方法进行低数据可解释的深度学习预测抗体黏度。
Sci Rep. 2023 Feb 20;13(1):2917. doi: 10.1038/s41598-023-28841-4.
5
Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.在早期发现阶段进行可开发性评估,以推动抗体衍生疗法的开发。
Antib Ther. 2022 Nov 11;6(1):13-29. doi: 10.1093/abt/tbac029. eCollection 2023 Jan.
6
An in silico method to assess antibody fragment polyreactivity.一种评估抗体片段多反应性的计算方法。
Nat Commun. 2022 Dec 7;13(1):7554. doi: 10.1038/s41467-022-35276-4.
7
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning.利用酵母展示筛选和机器学习降低治疗性抗体的自缔合。
MAbs. 2022 Jan-Dec;14(1):2146629. doi: 10.1080/19420862.2022.2146629.
8
Antibody apparent solubility prediction from sequence by transfer learning.通过迁移学习从序列预测抗体表观溶解度
iScience. 2022 Sep 22;25(10):105173. doi: 10.1016/j.isci.2022.105173. eCollection 2022 Oct 21.
9
Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space.使用能够推广到新突变空间的机器学习模型来优化治疗性抗体的亲和力和特异性。
Nat Commun. 2022 Jul 1;13(1):3788. doi: 10.1038/s41467-022-31457-3.
10
Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.等电点较弱的抗体可最大限度减少配方和生理胶体性质之间的权衡。
Mol Pharm. 2022 Mar 7;19(3):775-787. doi: 10.1021/acs.molpharmaceut.1c00373. Epub 2022 Feb 2.